People: Ibio Inc (IBIO.K)

IBIO.K on American Stock Exchange

0.42USD
23 Jul 2014
Price Change (% chg)

$0.01 (+2.44%)
Prev Close
$0.41
Open
$0.42
Day's High
$0.43
Day's Low
$0.38
Volume
249,806
Avg. Vol
142,540
52-wk High
$0.85
52-wk Low
$0.24

Search Stocks

Summary

Name Age Since Current Position

Robert Kay

73 2009 Executive Chairman of the Board, Chief Executive Officer

Robert Erwin

59 2008 President

Mark Giannone

57 2013 Chief Financial Officer

Andrea Corcoran

2012 Senior Vice President - Finance and Strategy

Terence Ryan

58 2012 Chief Scientific Officer

Seymour Flug

78 2012 Director

Glenn Chang

65 2008 Independent Director

Arthur Elliott

77 2010 Independent Director

James Hill

67 2008 Independent Director

John McKey

70 2008 Independent Director

Philip Russell

81 2010 Independent Director

Biographies

Name Description

Robert Kay

Mr. Robert B. Kay serves as Executive Chairman of the Board, Chief Executive Officer of iBio, Inc. He became a Director since the company became a publicly traded company in August 2008. Mr. Kay was a founder and senior partner of the New York law firm of Kay Collyer & Boose LLP, with a particular focus on mergers and acquisitions and joint ventures. He is also a principal and Chairman of Seaway Biltmore, Inc., a hotel ownership and management company. Mr. Kay received his B.A. from Cornell University’s College of Arts & Sciences and his J.D. from New York University Law School.

Robert Erwin

Mr. Robert L. Erwin serves as President of iBio, Inc., since August 2008. He Large Scale Biology Corporation from its founding in 1988 through 2003, including a successful initial public offering in 2000, and continued as non-executive chairman until 2006. He served as chairman of Icon Genetics AG from 1999 until its acquisition by a subsidiary of Bayer AG in 2006. From 2004 through 2007, Mr. Erwin served as managing director of Bio-Strategic Directors LLC, providing consulting services to the life sciences industry. He is currently chairman of Novici Biotech, a private biotechnology company, and a director of Resolve Therapeutics. Mr. Erwin’s non-profit work focuses on applying scientific advances to clinical medicine, especially in the field of oncology. He is co-founder, president and director of the Marti Nelson Cancer Foundation, Oncology. Mr. Erwin received his B.S. in Zoology with honors and M.S. in Genetics from Louisiana State University.

Mark Giannone

Mr. Mark Giannone is Chief Financial Officer of the iBio, Inc. He is a member of the accounting firm of Bosco Giannone LLC since its formation in 1999. His prior experience included employment as a senior accountant at Kenneth Leventhal & Co. (acquired by Ernst &Young LLP) and as a tax manager at BDO Seidman, a lecturer in various continuing education programs for the New York State Society of Certified Public Accountants and New York University. He is Chief Financial Officer of the Company.

Andrea Corcoran

Ms. Andrea J. Corcoran, JD., has been appointed as the Senior Vice President - Finance and Strategy of iBio, Inc. She joins iBio following roles with increasing responsibility for corporate, financial and business development strategy formation and operations at Idenix Pharmaceuticals, Inc., and Tolerx, Inc., each biopharmaceutical companies engaged in the discovery and development new and innovative pharmaceutical products.

Terence Ryan

Mr. Terence Ryan, Ph.D., serves as Chief Scientific Officer of iBio, Inc., since March 2012. He previously served as Assistant Vice President, Systems Biology at Wyeth Pharmaceuticals (later Pfizer, Inc.) from 2007-2010, and Director of Integrative Biology at GlaxoSmithKline from 2003-2007. He has also been Director, Cell Biology at Celera Genomics (2000-2003), and Associate Director of Cell Technologies and Protein Sciences at Regeneron Pharmaceuticals. He received his A.B. In Biology from Princeton University, and his M.S. and Ph.D. in Microbiology from Rutgers University. He also was a post-doctoral fellow in Molecular Virology at the University of Wisconsin.

Seymour Flug

Mr. Seymour Flug has been appointed as Director of iBio, Inc.He most recently was the former chairman, president and CEO of Diner’s Club International and a managing director at Citibank. Previously he served as a Senior Vice President at Hess Oil Company.

Glenn Chang

Mr. Glenn J. Chang, CPA., serves as an Independent Director of iBio, Inc., since August 2008. Since 1999 he has been Director, Executive Vice President and Chief Financial Officer of the First American International Bank, Brooklyn, N.Y. Prior to the founding of the Bank he spent almost 20 years at Citibank as Vice President. Mr. Chang is a Certified Public Accountant.

Arthur Elliott

Dr. Arthur Y. Elliott, Ph.D., serves as an Independent Director of iBio, Inc. He spent 16 years with Merck & Co., serving ultimately as Executive Director of Biological Operations, Merck Manufacturing Division, responsible for the bulk manufacture, testing, release and registration of all biological products sold. Dr. Elliott has served with the United States Department of Health and Human Services in the Avian Influenza Pandemic Preparedness Program in Washington, D.C. as Senior Program Manager for the Antigen Sparing Project since 2006. The program involves the cooperation of three pharmaceutical companies and four government groups (NIH, CDC, FDA, and HHS). While at Merck, he worked closely with both Merck Research Laboratories and the Merck Vaccine Division to forecast the timely transfer of technology for new and improved products from the research laboratories through the manufacturing area and into the marketing division for sales introductions. He has served as a biological consultant to the World Health Organization, National Institutes of Health, and The Bill & Melinda Gates Foundation. Dr. Elliott holds a Ph.D. in Virology from Purdue University, and an M.S. in Microbiology and a B.A. in Biology from North Texas State University. He serves as a member of the American Association for Advancement of Science, American Society for Microbiology, and American Tissue Culture Association.

James Hill

General (Retired) James T. Hill serves as an Independent Director of iBio, Inc., since August 2008. At the time of his retirement from active duty, General Hill was the Commander of the 4-Star United States Southern Command, reporting directly to the President and Secretary of Defense. As such he led all U.S. military forces and operations in Central America, South America and the Caribbean, worked directly with U.S. Ambassadors, foreign heads of state, key Washington decision-makers, foreign senior military and civilian leaders, developing and executing United States policy. His responsibilities included management, development and execution of plans and policy within the organization including programming, communications, manpower, operations, logistics and intelligence.

John McKey

Mr. John D. McKey, Jr., serves as an Independent Director of iBio, Inc., since August 2008. Since 2003, He has served as of counsel at McCarthy, Summers, Bobko, Wood, Sawyer & Perry, P.A. in Stuart, Florida, and previously was a partner from 1987 through 2003. From 1977 to 1987 Mr. McKey was a partner at Gunster Yoakley in Palm Beach, Florida. Mr. McKey received his B.B.A at the University of Georgia and his J.D. from the University of Florida College of Law.

Philip Russell

Maj. Gen(Retd.),Dr. Philip K. Russell, M.D., serves as an Independent Director of iBio, Inc. He served in the U.S. Army Medical Corps from 1959 to 1990, pursuing a career in infectious disease and tropical medicine research. Following his military service, he joined the faculty of Johns Hopkins University’s School of Hygiene and Public Health and worked closely with the World Health Organization as special advisor to the Children’s Vaccine Initiative. He was founding board member of the International AIDS Vaccine Initiative, and is an advisor to the Bill and Melinda Gates Foundation. He has served on numerous advisory boards of national and international agencies, including the Centers for Disease Control, National Institutes of Health, and the Institute of Medicine. He is the past Chairman of the Albert B. Sabin Vaccine Institute.

Basic Compensation

Name Fiscal Year Total

Robert Kay

589,288

Robert Erwin

519,288

Mark Giannone

--

Andrea Corcoran

--

Terence Ryan

200,000

Seymour Flug

--

Glenn Chang

--

Arthur Elliott

--

James Hill

--

John McKey

--

Philip Russell

--
As Of 29 Jun 2013

Options Compensation

Search Stocks